SHIN-ETSU-CHEMICAL
30.3.2022 08:02:57 CEST | Business Wire | Press release
Shin-Etsu Chemical Co., Ltd., (Head Office: Tokyo; President: Yasuhiko Saitoh) has developed a new series of products, the KCP Series, a new vulcanization type of one-component liquid silicone rubber.
One-component liquid silicone rubber cures at room temperature by reacting to the atmospheric humidity. After curing, because it has superior combined characteristics, including heat resistance, cold resistance, weather resistance and outstanding electrical properties, it is used as adhesive/sealing materials and coating materials in such products as component parts for electric vehicles (EV), semiconductors, and electric/electronics. Furthermore, because it cures at room temperature, it is not necessary to have a heating furnace and ultraviolet (UV) irradiation equipment. Accordingly, these new products will contribute to reducing environmental impact.
The KCP Series of products are a type that releases cyclopentanone*1 at the time of the curing reaction. This new product series will meet the expectations of our customers with its improved vulcanization characteristics, higher level of safety and excellent handleability compared to existing products.*2 The main characteristics of these new products are as follows:
1: The vulcanization speed is fast and also the adhesion develops quickly, and thus work efficiency improves. The tack-free time*3 of KCP-102 is 3 minutes, ½ of the time of the existing KE-4898-W*4 product.
2: The odor that is generated at the time of curing is lower, and has a higher level of safety.
3: Because the ignition temperature is high, at more than 70 ℃, the handling time and effort needed during the time of transport and storage can be reduced.
4: It exhibits good adhesion with various resins and also there are almost no corrosive effects on metals.*5
There are 3 products lined up in the KCP Series according to their viscosity index: KCP-100 (low viscosity), KCP-101 (mid-viscosity) and KCP-102 (paste type). All of them are tube-type, and one can work simply by pushing the contents out from the tube-type container. Going forward, Shin-Etsu Chemical will continue to strive to meet the requests of our customers and develop products that have various added functions as we work to expand the line-up of our products.
Shin-Etsu Chemical will continue to endeavor to enhance our ability to contribute to the solution of various social and customer issues by developing and supplying advanced functional silicone products through making full use of the technological power and knowhow that Shin-Etsu has nurtured up to now, as we work to further contribute to the realization of the sustainability of society.
Footnotes:
*1 Cyclopentanone is an organic compound represented by the chemical formula (CH2 )4 CO. It is one of the cyclic ketones and is a volatile colorless liquid.
*2 Existing products include types of acetic acid, oxime, alcohol and acetone, and each have their own characteristics.
*3 It is the time that it takes until when one touches the surface, it will not stick to one’s finger.
*4 Curing Condition: 23℃/50%Relative Humidity
*5 Metal substrates should be tested prior to use with this product to insure performance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220329006080/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PNCC Selects LotusFlare to Power Digital BSS and Commerce Platform for New 4G/5G Standalone Network26.2.2026 13:04:00 CET | Press release
LotusFlare, a provider of a cloud-native, AI-driven digital commerce and monetization platform for communications service providers (CSPs), today announced that Palau National Communications Corporation (PNCC) has selected it to provide a comprehensive commerce and monetization platform, including a full-stack digital business support system (dBSS) as part of PNCC’s broader 4G/5G Standalone (SA) network modernization programme. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226869218/en/ Palau National Communications Corporation (PNCC) The LotusFlare solution will support PNCC subscribers across mobile, fixed broadband, and digital TV services, while enabling unique multi-tenant capabilities aligned with PNCC’s long-term digital and regional strategy. PNCC has embarked on a comprehensive technology modernization program focused on increasing speed-to-market, enhancing customer experience, and long-term operational efficie
GoldState Music and Bridgepoint Announce Strategic Partnership Targeting Growth Investments26.2.2026 13:00:00 CET | Press release
Capital will support GoldState Music’s Growth Strategy which will invest in scalable, profitable music-oriented businesses across the music value chainBridgepoint commits a significant investment as lead investor in GoldState’s Growth Strategy Bridgepoint, one of the world’s leading mid-market investors, today announced that it has entered into a strategic partnership with GoldState Music, a premier music investment platform, committing a significant investment as lead investor in GoldState’s Growth Strategy. The capital will support a dedicated investment programme focused on building and scaling high-quality music-oriented businesses globally. GoldState Music is a private investment firm founded in 2022 by industry veteran Charles Goldstuck, who played an integral role in the development of many music enterprises as well as in the careers of numerous major artists and songwriters. The company’s Growth Strategy is focused on investing in and scaling growing businesses operating in the
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics26.2.2026 13:00:00 CET | Press release
Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar lung cancer market. Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-small cell lung cancer (NSCLC): CL-273, a pre-IND, reversible, wild-type-sparing pan-EGFR inhibitor, and CL-741, a Phase 1-ready, orally available type IIb c-MET kinase inhibitor. John Yu, M.D., Kairos Pharma Chief Executive Officer, commented: "We anticipate this acquisition will significantly
Amazfit Introduces the Active 3 Premium: Turning Daily Movement into Meaningful Progress for Entry-Level Runners26.2.2026 13:00:00 CET | Press release
Premium materials, a 12-day battery life and new running features provide support for those kicking off their running journey Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced the Amazfit Active 3 Premium, a compact, 4-button smartwatch designed as an entry point into structured running and hybrid training. Made for athletes building consistency across different forms of training, the Active 3 Premium supports road running and hybrid routines that combine endurance, strength, and studio-based workouts. Its compact design makes it easy to train across environments, from neighborhood runs to studio floors, offering a capable, approachable experience without feeling overbuilt or intimidating. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226378156/en/ Made for athletes building consistency across different forms of training, the Active 3 Premium supports road running and hybrid routines th
Wyss Geneva Spin-Off Clee Medical Secures Seed Financing to Bring Real-Time Vision to Brain Surgery26.2.2026 12:49:00 CET | Press release
The Wyss Center for Bio and Neuroengineering Geneva announced today the successful closing of the Seed financing round of Clee Medical SA, a Swiss neurotechnology spin-off developing ultra-high-resolution real-time intraoperative imaging for brain surgery. The round was led by High-Tech Gründerfonds (HTGF), with participation from Zürcher Kantonalbank (ZKB), Kickfund, FONGIT, and Venture Kick joining existing investors Wyss Center Geneva. Clee Medical spun-out from Wyss Geneva’s Minimally Invasive Intracranial Access (MICA) research project in December 2024. Its flagship platform, Neuro Access, combines OCT imaging with advanced navigation to help neurosurgeons visualize brain anatomy and critical structures in real time during stereotactic procedures. “Clee Medical not only holds the promise of improving patient outcomes but also highlights Wyss Geneva’s dedication to bridging the gap between scientific discovery and real-world impact.” Dr. Erwin Böttinger, CEO, Wyss Geneva “Neurosurg
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
